A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
Study Identifier:
ACH471-204
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
- Drug: Placebo
Date
Jun 2018 - Dec 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 17 - 65 Years
Requirements Information
Sex
Female & Male
Age
17 - 65 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
- Drug: Placebo
Date
Jun 2018 - Dec 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 17 - 65 Years years
Requirements Information
Protocol Summary
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant proteinuria attributable to C3G.
Trial Locations
Location
Status
Location
Clinical Study Site
Aurora, Colorado, United States, 80045
Status
N/A
Location
Clinical Study Site
Lawrenceville, Georgia, United States, 30046
Status
N/A
Location
Clinical Study Site
Iowa City, Iowa, United States, 52242
Status
N/A
Location
Clinical Study Site
Baltimore, Maryland, United States, 21205
Status
N/A
Location
Clinical Study Site
New York, New York, United States, 10016
Status
N/A
Location
Clinical Study Site
New York, New York, United States, 10032
Status
N/A